
From: Robert Davis [/O=REGENERON/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=ROBERT.DAVIS]
Sent: Friday, January 10, 2014 9:48:56 PM
To: William Daniels; Robert Krukowski
Subject: RE: Chronic Disease Fund
Attachments: image001.png

Ok tell him that the \$12.75 million amount was decided by Len and Bob Landry. Additionally we will review on a quarterly basis to determine what we need to provide for Wet AMD patients. We will determine our contributions based on company cash as well. It's hard to give a firm number and he can also ask Dressel what he has budgeted for 2014.

Thank you,

Bob

Robert C. Davis U.S. | **Executive Director** & Head of Trade, Reimbursement & Managed Markets
REGENERON Pharmaceuticals, Inc. | 777 Old Saw Mill River Road | Tarrytown, NY 10591
Tel: [REDACTED] | Fax: 914.931-2017 | Cell: [REDACTED] | Email [REDACTED]

REGENERON

Trade, Reimbursement & Managed Markets

From: William Daniels
Sent: Friday, January 10, 2014 4:18 PM
To: Robert Krukowski; Robert Davis
Subject: Fwd: Chronic Disease Fund

Direction please!

Bil Daniels
Regeneron
[REDACTED]

Sent from my iPhone

Begin forwarded message:

From: Leonard Brooks <[REDACTED]>
Date: January 10, 2014 at 4:05:11 PM EST
To: William Daniels [REDACTED]>
Subject: Chronic Disease Fund

Hi William,
I am part of the treasury team and work closely with A/P regarding payments. I know there is another significant payment that was just dropped off with A/P. Can you give me an idea of how our payments are structured to this fund (and amounts, or estimates, if possible) so that I can put these as part of our cash

forecast since the payments are so significant when they do occur.
Thank you.
Len

Len Brooks | Director - Liquidity

REGENERON Pharmaceuticals, Inc. | 777 Old Saw Mill River Road | Tarrytown, NY 10591

Tel: [REDACTED] | Cell: [REDACTED] | Email: [REDACTED]